FOLFIRI + FOLFOX6/FOLFOX7 + S241656 + PANITUMUMAB + Cetuximab for histiocytosis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 28 Mar 2023: Trial registered, NCT05786924
  2. 18 Apr 2023: Trial started, NCT05786924

The trials

NCT05786924: Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

State
Under way
Phase
Phase 1 and Phase 2
People
623 planned
Started
18 Apr 2023
Primary completion
Jun 2028
Arms
Part 1D: Dose Escalation CRC, Part 2D1: Dose Expansion CRC
Results
None posted
  1. 28 Mar 2023: Trial registered
  2. 18 Apr 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.